...
首页> 外文期刊>Endocrine. >Shear wave elastography and Afirma gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study
【24h】

Shear wave elastography and Afirma gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study

机译:剪切波弹性造影和AFIRMA基因表达分类在甲状腺结节中具有不确定细胞学:比较研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose To compare shear wave elastography (SWE) and Afirma? gene expression classifier (GEC) for diagnosis of malignancy in thyroid nodules (TNs) with Bethesda Classification (BC) III or IV indeterminate cytology. Methods This preliminary single-center prospective study was approved by the Institutional Review Board. We evaluated 151 consented patients with 151 indeterminate TNs (123 BC III, 28 BC IV) on fine-needle aspiration biopsy (FNAB). B-mode ultrasound, vascularity, and SWE were performed prior to FNAB. TN stiffness was measured as shear wave velocity (SWV) in meters per second (m/s). The stiffest area of the TN was selected for SWV measurement. GEC testing was performed with a second FNAB. Surgery was recommended for GEC-suspicious TNs, or GEC-benign TNs with two or more worrisome B-mode US features. Results Surgical pathology confirmed 31 malignant TNs. Among the GEC-suspicious group, 28 of 59 TNs were malignant. The SWV value of ≥3.59 m/s was the best cut-off for malignancy risk based on the receiver operating curve (ROC). Twenty-six malignant TNs had SWV ≥ 3.59 m/s. The sensitivity and specificity for SWV ≥ 3.59 m/s were 83.9 and 79.2%, respectively. Positive predictive value (PPV) was 51.0% and negative predictive value (NPV) was 95.0%. For the GEC-suspicious group, sensitivity, specificity, PPV, and NPV were 90.3, 74., 47.5, and 96.7%, respectively. In multivariate analysis, SWV and GEC-suspicious were significant predictors of malignancy, but B-mode features and vascularity were not. Conclusion This preliminary study indicates that SWE and GEC are independent predictors of malignancy in TNs with BC III or IV.
机译:比较剪力波弹性摄影(SWE)和Afirma的目的?基因表达分类剂(GEC)用于诊断甲状腺结节(TNS)的恶性肿瘤(BC)III或IV不确定细胞学。方法采用机构审查委员会批准了这项初步单中心的前瞻性研究。我们评估了151名患者的151名患者在细针吸入活检(FNAB)上不确定TNS(123 BC III,28 BC IV)。在FNAB之前进行B模式超声,血管性和SWE。将TN刚度作为剪力波速度(SWV)以米为单位(M / s)。选择TN的最硬质面积用于SWV测量。 GEC测试用第二个FNAB进行。推荐用于GEC-SEACIOCT TNS的手术,或GEC-良性TNS,具有两个或多个令人担忧的B模式美国功能。结果外科病理学确认了31个恶性TNS。在GEC-可疑组中,59个TNS中的28个是恶性的。 SWV值≥3.59m/ s是基于接收器运行曲线(ROC)的恶性风险最佳截止。二十六个恶性TNS具有SWV≥3.59米/秒。 SWV≥3.59m/ s的敏感性和特异性分别为83.9和79.2%。阳性预测值(PPV)为51.0%,阴性预测值(NPV)为95.0%。对于GEC-可疑的组,敏感性,特异性,PPV和NPV分别为90.3,74,47.5和96.7%。在多变量分析中,SWV和GEC-SACKICOUS是显着的恶性肿瘤预测因子,但B模式特征和血管不。结论这项初步研究表明,SWE和GEC是具有BC III或IV的TNS中恶性肿瘤的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号